D

espite widespread optimism about the tax cut bill racing through Congress, biopharma insiders across the U.S. say they’re not expecting to add new jobs at their companies in the coming year, a new STAT Plus survey finds.

Nearly 6 in 10 respondents said it’s unlikely their companies will be expanding. Nonetheless, they remain bullish on the industry at large, with more than half expressing strong confidence that biotech will have a good year.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.